Summary
None of the 21 patient-assistance, operational, contact, timing, insurance, or generic-program claims is supported by the supplied FDA prescribing information. The label sections provided are empty, so the claims cannot be verified against the label.
Category Scores
Accurate Statements
Unsupported Statements
The Vascepa patient-support website provides an enrollment form, an income-verification worksheet, and prescription-transfer documents as printable PDFs.
Absent from the supplied prescribing information.
A doctor's office can request Vascepa assistance forms through the patient-support portal.
Absent from the supplied prescribing information.
The Vascepa enrollment form collects the applicant's name, address, date of birth, and insurance details.
Absent from the supplied prescribing information.
The Vascepa enrollment form includes a signed release allowing the assistance program to verify coverage.
Absent from the supplied prescribing information.
The Vascepa financial worksheet requests household income and the number of dependents.
Absent from the supplied prescribing information.
The Vascepa financial worksheet requests recent tax documents or pay stubs.
Absent from the supplied prescribing information.
The prescriber must complete the prescription and medical-necessity section of the Vascepa assistance forms.
Absent from the supplied prescribing information.
Most Vascepa assistance applications are processed within two business days after the complete packet is received.
Absent from the supplied prescribing information.
If documentation is missing, the Vascepa assistance program contacts the applicant or the applicant's doctor within 24 hours.
Absent from the supplied prescribing information.
After approval, the Vascepa benefit card or copay assistance is usually active the same day.
Absent from the supplied prescribing information.
The Vascepa support line is 1-855-VASCEPA (1-855-827-2372).
Absent from the supplied prescribing information.
A Vascepa support-line representative can conduct the application questions by phone and mail or fax the completed forms for signature.
Absent from the supplied prescribing information.
When insurance changes, the Vascepa assistance program re-verifies coverage.
Absent from the supplied prescribing information.
After an insurance change, the Vascepa assistance program usually issues updated benefit information within one business day.
Absent from the supplied prescribing information.
Failure to update insurance information can result in a temporary hold on Vascepa assistance until the new insurance details are confirmed.
Absent from the supplied prescribing information.
Amarin's patient navigators can answer questions about Vascepa assistance-program eligibility, required signatures, and submission of supporting documents.
Absent from the supplied prescribing information.
Pharmacies that stock Vascepa may keep blank assistance-program forms and fax them to the assistance program.
Absent from the supplied prescribing information.
The Vascepa copay-assistance program runs through December 2024 and is renewed annually.
Absent from the supplied prescribing information.
The launch of generic icosapent ethyl typically causes the brand-name Vascepa copay card to sunset.
Absent from the supplied prescribing information.
Some generic icosapent ethyl manufacturers offer their own patient-assistance programs.
Absent from the supplied prescribing information.
Benefits and eligibility rules differ among generic icosapent ethyl patient-assistance programs.
Absent from the supplied prescribing information.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Moderate
The claims concern access-program procedures, contact information, eligibility, processing times, and benefit status. Although they do not directly conflict with any supplied label statement, unsupported operational details could misdirect patients or prescribers about how to obtain assistance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
All claims are absent from the supplied FDA prescribing information and therefore cannot be presented as label-supported information.
Suggested Improvement
Remove or separately qualify the patient-assistance and generic-program claims as non-label information, and verify them against current official program materials before use.